M&A Deal Summary

Danaher Acquires Abcam

On August 28, 2023, Danaher acquired life science company Abcam for 5.7B USD

Acquisition Highlights
  • This is Danaher’s 8th transaction in the Life Science sector.
  • This is Danaher’s 5th largest (disclosed) transaction.
  • This is Danaher’s 2nd transaction in the United Kingdom.

M&A Deal Summary
Date 2023-08-28
Target Abcam
Sector Life Science
Buyer(s) Danaher
Deal Type Add-on Acquisition
Deal Value 5.7B USD

Target

Abcam

Cambridge, United Kingdom
website
Abcam is a producer and marketer of high quality protein research tools. These tools enable life scientists to analyze components of living cells at the molecular level which is essential in a wide range of fields including drug discovery, diagnostics, and basic research. Abcam was founded in 1998 and is based in Cambridge, the United Kingdom.

Search 192,800 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Danaher

Washington, District of Columbia, United States

website

Category Company
Founded 1969
Sector Diversified
Employees79,000
Revenue 31.5B USD (2022)
DESCRIPTION

Danaher designs, manufactures and markets professional, medical, industrial and commercial products and services. Danaher's research and development, manufacturing, sales, distribution, service and administrative facilities are located in more than 50 countries. Danaher's business consists of five segments: Test & Measurement; Environmental; Life Sciences & Diagnostics; Dental; and Industrial Technologies. Danaher was incorporated in 1969 and is based in Washington, DC.

DEAL STATS #
Overall 42 of 42
Sector (Life Science) 8 of 8
Type (Add-on Acquisition) 38 of 38
Country (United Kingdom) 2 of 2
Year (2023) 1 of 1
Size (of disclosed) 5 of 23
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-06-17 Aldevron

Fargo, North Dakota, United States

Aldevron serves the biotechnology industry with the custom production of nucleic acids, proteins, and antibodies. Thousands of clients use Aldevron-produced plasmids, RNA, and gene editing enzymes for projects ranging from discovery research to clinical trials to commercial applications. These products are critical raw materials and key components in commercially available drugs and medical devices. Aldevron was founded in 1998 and is based in Fargo, North Dakota.

Buy $9.6B
Mergr

Product

Company

Legal